ReviewBreast cancer (Dove Medical Press)2012
Targeting γ-secretase in breast cancer.
Review in Breast cancer (Dove Medical Press), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer.World journal of clinical oncology · 2025Article
- The Intricate Notch Signaling Dynamics in Therapeutic Realms of Cancer.ACS pharmacology & translational science · 2023Review
- CAFuncAPA: a knowledgebase for systematic functional annotations of APA events in human cancers.NAR cancer · 2023Article
- Tumor microenvironment pathways: Cross regulation in breast cancer metastasis.Genes & diseases · 2022Review
- DAPT Attenuates Cadmium-Induced Toxicity in Mice by Inhibiting Inflammation and the Notch/HES-1 Signaling Axis.Frontiers in pharmacology · 2022Article
- γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression.International journal of medical sciences · 2021Article
- Hair Cell Generation in Cochlear Culture Models Mediated by Novel γ-Secretase Inhibitors.Frontiers in cell and developmental biology · 2021Article
- Pharmacological disruption of the Notch transcription factor complex.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ.Scientific reports · 2019Article
- Evaluation of the prognostic significances of γ-secretase genes in pancreatic cancer.Oncology letters · 2019Article
- b-Annulated 1,4-dihydropyridines as Notch inhibitors.Bioorganic & medicinal chemistry letters · 2018Article
- Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells.BMC genomics · 2015Article
- New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.World journal of clinical cases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
γ-secretase complexes are multisubunit protease complexes that perform the intramembrane cleavage of more than 60 type-I transmembrane proteins, including Notch receptors. Since dysregulated Notch signaling has been implicated in the tumorigenesis and progression of breast cancer, small molecule γ-secretase inhibitors (GSIs) are being tested for their therapeutic potential in breast cancer treatment in several clinical trials. Here, the structure of γ-secretase complex and the development of GSIs are briefly reviewed, the roles of Notch and several other γ-secretase substrates in breast cancer are discussed, and the difference between γ-secretase inhibition and Notch inhibition, as well as the side effects associated with GSIs, are described. A better understanding of molecular mechanisms that affect the responsiveness of breast cancer to GSI might help to develop strategies to enhance the antitumor activity and, at the same time, alleviate the side effects of GSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.